Bleocin Warnings

(1) Serious pulmonary manifestation such as interstitial pneumonia and pulmonary fibrosis may occur due to administration of Bleocin, with occasional fatal outcome. Therefore, Bleocin must be administered only to patients who are considered appropriate for treatment of Bleocin. In addition, patients should be monitored by a physician during treatment with Bleocin and for a certain period (approximately 2 months) after the completion of administration. Particularly, administration of Bleocin to the elderly of age of 60 or over or patients with underlying diseases in the lung should only be performed after full consideration of "Precautions". When early symptoms such as exertional dyspnea, fever, cough, crepitations (rales), abnormal chest radiographs, and abnormality of alveolar-arterial oxygen difference (A-aDO₂), partial pressure of arterial oxygen (PaO₂), or diffusing capacity for carbon monoxide (DL_CO) are identified, Bleocin should be immediately discontinued and appropriate measures should be taken.
(2) Cancer combination chemotherapy including Bleocin should be performed only in patients who are considered appropriate for the therapy under the supervision of a physician with adequate experience in cancer chemotherapy at a medical facility fully equipped for emergency treatment. Furthermore, much attention should be paid to select appropriate patients by referring the package inserts of each combined drug.